2012 AACR: Discovery of potent dual inhibitors of both XIAP and cIAP using fragment based

/in , ,

2012 AACR: Discovery of potent dual inhibitors of both XIAP and cIAP using fragment based

2012 ASCO: Phase I Study Assessing QDx2 schedule of AT13387 in Advanced Solid Tumors

/in , ,

2012 ASCO: Phase I Study Assessing QDx2 schedule of AT13387 in Advanced Solid Tumors

2012 TAT: Discovery of Dual Antagonist of both XIAP and cIAP Using Fragment Based Drug Discovery

/in , ,

2012 TAT: Discovery of Dual Antagonist of both XIAP and cIAP Using Fragment Based Drug Discovery

2012 AACR: AT13387, HSP90 inhibitor effective in vemurafenib-sensitive and -resistant melanoma model

/in , ,

2012 AACR: AT13387, HSP90 inhibitor effective in vemurafenib-sensitive and -resistant melanoma model

2012 Thoracic Symposium: HSP90 Inhibitor AT13387 Effective in Mutant EGFR and ALK-Positive NSCLC

/in , ,

2012 Thoracic Symposium: HSP90 Inhibitor AT13387 Effective in Mutant EGFR and ALK-Positive NSCLC

2011 TAT_Discovery and Development of Next Generation Epigenetic DNMT Inhibitor SGI-110

/in , ,

2011 TAT_Discovery and Development of Next Generation Epigenetic DNMT Inhibitor SGI-110

2011 EORTC: AT13387 Anti-Tumor Activity in imatinib-sensitive and -resistant GIST Models

/in , ,

2011 EORTC: AT13387 Anti-Tumor Activity in imatinib-sensitive and -resistant GIST Models

2010 ASCO: HSP90 Inhibitor in Refractory Solid Tumors: Phase I Study of AT13387

/in , ,

2010 ASCO: HSP90 Inhibitor in Refractory Solid Tumors: Phase I Study of AT13387